Peter Attia· MD
and and you know i i i kind of agree with everything you said about about why you know if you're gonna pick one regimen for rapamycin that makes sense and and and like you said it's really based on two clinical trials right i mean really uh and so it's a limited data set but at least for immune function in people um you know it seemed to work and and that's actually i mean you know we could we could spend hours talking about this because that's a whole nother i think uh interesting and informative sort of experience was was the failure of the phase three clinical trial at restore bio right and and what happened there and i don't think we actually it's at least not in the it's not published yet